Holen Sie sich die Stockscreener-App
15.60
0.83%
-0.13
Handel nachbörslich:
15.60
Schlusskurs vom Vortag:
$15.73
Offen:
$15.92
24-Stunden-Volumen:
734.04K
Relative Volume:
0.49
Marktkapitalisierung:
$1.60B
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-5.3979
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
-7.42%
1M Leistung:
-17.59%
6M Leistung:
+47.59%
1J Leistung:
-11.21%
1-Tages-Spanne:
$15.54
$16.33
1-Wochen-Bereich:
$15.33
$16.97
52-Wochen-Spanne:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
15.60 | 1.62B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight - MarketBeat
Does Nurix Therapeutics Inc. have a sustainable dividendJuly 2025 Institutional & Entry Point Confirmation Signals - mfd.ru
Is Nurix Therapeutics Inc. undervalued by DCF analysisQuarterly Portfolio Report & Accurate Entry/Exit Alerts - mfd.ru
What is the long term forecast for Nurix Therapeutics Inc. stockEarnings Summary Report & Reliable Trade Execution Plans - mfd.ru
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Why Nurix Therapeutics Inc. stock remains resilient2025 Earnings Impact & Daily Technical Stock Forecast Reports - mfd.ru
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Canada
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - Sahm
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
Stifel raised Nurix Therapeutics, Inc. (NRIX) price target to $35 and maintains buy ahead of 2026 catalysts - MSN
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Is Nurix Therapeutics Inc forming a bullish divergenceWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Finviz
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Finviz
Research Analysts Offer Predictions for NRIX Q1 Earnings - MarketBeat
Published on: 2026-02-01 10:49:34 - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - 富途牛牛
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking A 70% Upside Potential - DirectorsTalk Interviews
Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure - The Globe and Mail
Nurix Therapeutics chief legal officer Ring sells $73k in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics chief legal officer Ring sells $73k in stock - Investing.com UK
Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,895 Shares - MarketBeat
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Finviz
Nurix Therapeutics CSO Gwenn Hansen sells $81k in shares By Investing.com - Investing.com Canada
Nurix Therapeutics CFO Hans van Houte sells $61k in shares - Investing.com Canada
Big Picture: Can Artius II Acquisition Inc Equity Right be the next market leaderWeekly Stock Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Should I buy Nurix Therapeutics Inc stock now2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - Sahm
Stock Analysis: Will Nurix Therapeutics Inc be affected by tariffsQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Momentum Shift: Can THTX expand into new marketsMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
HC Wainwright Raises Price Target for NRIX, Reaffirms Buy Rating - GuruFocus
Nurix Therapeutics price target raised to $35 from $33 at Stifel - TipRanks
Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t - GuruFocus
Royal Bank Of Canada Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
NRIX: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus
NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating - GuruFocus
NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig - GuruFocus
NRIX Analyst Jeet Mukherjee Reiterates Buy Rating, Target Stays at $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Earns "Buy" Rating from BTIG Research - MarketBeat
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo - TipRanks
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler - TipRanks
NRIX: Needham Reiterates Buy Rating with Stable Price Target | N - GuruFocus
What 11 Analyst Ratings Have To Say About Nurix Therapeutics - Benzinga
A Look At Nurix Therapeutics (NRIX) Valuation As DAYBreak Phase 2 Trial Progresses - Sahm
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):